Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR-T cells targeting CD19 and CD22-Zhejiang University-B-cell acute lymphoblastic leukemia
- Development stage
- Unknown
- Lead developer
- Zhejiang University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
This is an investigational, site-specific sequential **autologous CAR-T-cell therapy regimen** developed at Zhejiang University for adults with newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia. It consists of separately manufactured CAR-T-cell products directed first against **CD19** and subsequently against **CD22**, two B-cell surface antigens expressed by leukemic blasts. The regimen was studied with dasatinib in the completed single-center NCT04788472 trial; dasatinib is a concomitant therapy and is not an intrinsic component of the CAR-T-cell product regimen. No INN, commercial brand name, or single sponsor development code for the complete sequential CD19/CD22 CAR-T regimen has been identified.
- Other names
- CD19 and CD22 CAR-T cellsCD-19 and CD22 CAR-T cellsCD 19 and CD22 CAR-T cellsSequential CD19 and CD22 CAR-T therapy
02
Targets
CD19 (B lymphocyte antigen CD19)CD22 (Cluster of Differentiation 22)
Beyond the preview
Go deeper on CAR-T cells targeting CD19 and CD22-Zhejiang University-B-cell acute lymphoblastic leukemia.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR-T cells targeting CD19 and CD22-Zhejiang University-B-cell acute lymphoblastic leukemia.